biotech / news / / The Manila Times
Isomorphic Labs will use the funding to power its world-leading AI drug design engine, scale its business globally and progress its drug candidate pipeline.
Isomorphic Labs has raised $2.1 billion in Series B funding led by Thrive Capital.
KEY POINTS
- The funding will accelerate development and global scaling of Isomorphic Labs' AI drug design engine, IsoDDE.
- New investors include MGX, Temasek, CapitalG, and the UK Sovereign AI Fund.
- Isomorphic Labs recently published new IsoDDE capabilities bridging protein structure prediction and real-world drug discovery.
- Strategic partnerships with Novartis, Lilly, and Johnson & Johnson validate Isomorphic's AI-first drug discovery approach.
COMPANIES
Summarized by Newsio from The Manila Times. How we summarize →